Caxton Associates (New York)’s Gilead Sciences GILD Stock Holding History

Caxton Associates (New York)’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$524K	Sell	5,671 -11,929	-68%	-$1.07M	0.02%	320
2024 Q3	$1.48M	Buy	+17,600	New	+$1.34M	0.06%	178
2024 Q2	–	Sell	-12,141	Closed	-$889K	–	523
2024 Q1	$889K	Hold	12,141	–	–	0.05%	245
2023 Q4	$984K	Hold	12,141	–	–	0.05%	229
2023 Q3	$910K	Buy	12,141 +3,436	+39%	+$264K	0.13%	169
2023 Q2	$671K	Buy	+8,705	New	+$694K	0.1%	213
2023 Q1	–	Sell	-769,230	Closed	-$66M	–	545
2022 Q4	$66M	Buy	+769,230	New	+$60.9M	4.41%	5
2020 Q3	–	Sell	-6,247	Closed	-$481K	–	394
2020 Q2	$481K	Buy	+6,247	New	+$479K	0.04%	148
2019 Q2	–	Sell	-3,219	Closed	-$209K	–	450
2019 Q1	$209K	Buy	+3,219	New	+$214K	0.03%	328
2018 Q2	–	Sell	-13,202	Closed	-$995K	–	411
2018 Q1	$995K	Buy	+13,202	New	+$1.05M	0.05%	186
2014 Q2	–	Sell	-50,000	Closed	-$3.89M	–	206
2014 Q1	$3.54M	Buy	+50,000	New	+$3.92M	0.22%	84
2013 Q4	–	Sell	-250,000	Closed	-$15.7M	–	248
2013 Q3	$15.7M	Buy	250,000 +125,000	+100%	+$7.47M	0.82%	32
2013 Q2	$6.41M	Buy	+125,000	New	+$6.52M	0.32%	75

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caxton Associates (New York)'s GILD Position: Q4 2024 in Review

Caxton Associates (New York) reduced its Gilead Sciences (GILD) stake by 68% in Q4 2024, selling an estimated $1.07M and leaving 5,671 shares worth $524K. The position accounts for 0.02% of the portfolio, ranked #320.

Caxton Associates (New York) first reported a position in GILD in Q2 2013 and has held it in 13 quarters since. The position peaked at $66M in Q4 2022. 1,887 funds tracked by Wall St. Rank hold GILD as of Q4 2024.

Caxton Associates (New York) held 5,671 shares of Gilead Sciences worth $524K as of Q4 2024.
Caxton Associates (New York) sold 11,929 Gilead Sciences shares in Q4 2024, an estimated $1.07M.
Gilead Sciences made up 0.02% of Caxton Associates (New York)'s portfolio in Q4 2024, its #320 holding.
Caxton Associates (New York) first reported a position in Gilead Sciences in Q2 2013 and has held it in 13 quarters since.
Caxton Associates (New York)'s Gilead Sciences position peaked at $66M in Q4 2022.
1,887 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.